These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 17638393)

  • 1. Nucleoside and nucleotide reverse transcriptase inhibitors in children.
    Giaquinto C; Rampon O; Penazzato M; Fregonese F; De Rossi A; D'Elia R
    Clin Drug Investig; 2007; 27(8):509-31. PubMed ID: 17638393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study.
    Yang WL; Kouyos RD; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Hirzel C; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF; ;
    J Antimicrob Chemother; 2015 Dec; 70(12):3323-31. PubMed ID: 26362944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ideal nucleoside/nucleotide backbone.
    Gallant JE
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S44-51. PubMed ID: 15319669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
    Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
    Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.
    Hammer SM
    Top HIV Med; 2006; 14(4):140-3. PubMed ID: 17114828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future antiretroviral treatment options in paediatric HIV infection.
    Giaquinto C; Morelli E; Fregonese F; Rampon O; Penazzato M; de Rossi A; D'Elia R
    Clin Drug Investig; 2008; 28(6):375-97. PubMed ID: 18479179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
    Piliero PJ
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New nucleoside/nucleotide backbone options: a review of recent studies.
    Ruane PJ; DeJesus E
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Aug; (8):CD008651. PubMed ID: 20687097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
    Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.
    Bhana N; Ormrod D; Perry CM; Figgitt DP
    Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple nucleoside reverse transcriptase inhibitor therapy in children.
    Handforth J; Sharland M
    Paediatr Drugs; 2004; 6(3):147-59. PubMed ID: 15170362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An introduction to nucleoside and nucleotide analogues.
    Squires KE
    Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.
    Cihlar T; Ray AS
    Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.